Fifth Third Bancorp Boosts Holdings in ANI Pharmaceuticals, Inc. $ANIP

Fifth Third Bancorp raised its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 17,255.6% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 9,372 shares of the specialty pharmaceutical company’s stock after acquiring an additional 9,318 shares during the quarter. Fifth Third Bancorp’s holdings in ANI Pharmaceuticals were worth $721,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals in the first quarter valued at about $28,000. Hantz Financial Services Inc. increased its stake in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after acquiring an additional 249 shares during the period. Kemnay Advisory Services Inc. purchased a new position in ANI Pharmaceuticals during the fourth quarter worth about $48,000. State of Wyoming purchased a new position in ANI Pharmaceuticals during the second quarter worth about $50,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in ANI Pharmaceuticals by 30.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock valued at $86,000 after purchasing an additional 253 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analysts Set New Price Targets

ANIP has been the topic of several recent analyst reports. Canaccord Genuity Group assumed coverage on ANI Pharmaceuticals in a research report on Thursday, July 16th. They set a “hold” rating and a $91.00 target price on the stock. Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Guggenheim reissued a “buy” rating and issued a $124.00 target price on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Finally, Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Six investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $105.00.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, Director Thomas Haughey sold 2,000 shares of the business’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.88, for a total transaction of $161,760.00. Following the sale, the director directly owned 38,878 shares in the company, valued at approximately $3,144,452.64. The trade was a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 3,313 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total value of $284,918.00. Following the completion of the sale, the chief financial officer directly owned 177,543 shares in the company, valued at $15,268,698. This trade represents a 1.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 85,179 shares of company stock valued at $6,722,596 in the last 90 days. 8.10% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Trading Up 0.9%

Shares of ANI Pharmaceuticals stock opened at $78.37 on Tuesday. The company has a 50-day moving average of $81.24 and a two-hundred day moving average of $79.48. ANI Pharmaceuticals, Inc. has a 12-month low of $62.60 and a 12-month high of $99.50. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06. The stock has a market cap of $1.78 billion, a PE ratio of 19.84 and a beta of 0.43.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. The business had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company’s quarterly revenue was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts anticipate that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.